OncoMed is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutic candidates directed to fundamental biologic pathways and targets thought to drive cancer’s growth, resistance, recurrence, and metastasis. The company offers several therapeutic candidates specifically targeting cancer stem cell pathways and it has an emerging pipeline of immuno-oncology therapeutic candidates that aim to bolster immune system recognition of cancer cells and/or suppress immune system evasion mechanisms.